Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
180 hedge funds and large institutions have $1.86B invested in Portola Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 70 increasing their positions, 53 reducing their positions, and 49 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 53
28% more call options, than puts
Call options by funds: $84.1M | Put options by funds: $66M
16% less funds holding
Funds holding: 215 → 180 (-35)
34% less capital invested
Capital invested by funds: $2.82B → $1.86B (-$955M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
65% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$132M |
| 2 |
State Street
Boston,
Massachusetts
|
+$33.5M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$33.4M |
| 4 |
PA
Perceptive Advisors
New York
|
+$19.3M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$98.4M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$28.6M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$27.7M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$27M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$26.3M |
PTLA Hedge Fund Activity: Q1 2018 in Review
180 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2018, worth a combined $1.86B — down 34% from $2.82B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of PTLA and 17 opened new positions — a net loss of 32 holders — while 53 trimmed existing stakes and 70 added.
The largest buyer was Wellington Management Group, adding an estimated $132M. The largest seller was Fidelity Investments, cutting an estimated $98.4M.
- 180 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2018, down from 215 in Q4 2017.
- Funds reported $1.86B of Portola Pharmaceuticals, Inc. stock for Q1 2018, down 34% quarter-over-quarter.
- 17 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2018 and 49 closed out, a net change of -32 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q1 2018 was Wellington Management Group, an estimated $132M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q1 2018 was Fidelity Investments, an estimated $98.4M sold.
Based on aggregated 13F filings for Q1 2018.